New drug combo aims to boost leukemia treatment
NCT ID NCT05993949
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This early-phase study tests whether adding a short course of the drug dasatinib can make CAR T-cell therapy more manageable for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Eight participants receive dasatinib pills for three days each week during the first month after their CAR T-cell infusion. The main goal is to see if this schedule is feasible and safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.